• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

Equistone sells Audley Travel to 3i

  • Greg Gille
  • Greg Gille
  • @unquotenews
  • 22 December 2015
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

3i has acquired Audley Travel, a UK-based bespoke travel company, from Equistone.

3i Group invested £159m in exchange for a majority stake in the business. Equistone declined to comment on the company's total enterprise value and the returns generated upon the exit.

Equistone purchased Audley Travel for an estimated £95m in 2012, with Barclays and RBS providing debt facilities. The GP invested via its Equistone Fund IV vehicle, which closed on €1.5bn at the beginning of 2013.

Audley Travel

  • DEAL:

    SBO

  • VALUE:

    <£200m est

  • LOCATION:

    Witney

  • SECTOR:

    Travel & tourism

  • FOUNDED:

    1996

  • TURNOVER:

    £165m (2015 est)

  • STAFF:

    380

  • VENDOR:

    Equistone

This marks the third exit from the fund, which is understood to have returned between 50-60% of commitments to its investors following the Audley Travel deal.

During the investment period, Equistone installed a new CEO and chair for the business, which went on to expand internationally with the opening of an office in the US. Revenues doubled to reach £165m across that same time-frame.

Management reinvested alongside 3i in this latest transaction and will look to pursue the same growth strategy in the coming years - namely bolstering the company's UK presence, developing the US activities and expanding into new international markets.

Company
Established in 1996, Audley Travel designs bespoke holidays to 80 countries for UK and US customers. The business is headquartered in Witney with offices in London and Boston.

Audley Travel employs 380 staff and is expected to see annual revenues grow by 20% to a forecast £165m in 2015. In its 2014 accounts, the company reported sales of £135m with an EBITDA margin of around 11%, with operating profits coming in at around £15m.

People
Tom Salmon represented 3i on the deal. Equistone was represented by Phil Griesbach and Joyce Church.

Advisers
Equity - Baird (Corporate finance); Ropes & Gray (Legal); Deloitte (Financial due diligence, tax); Parthenon (Commercial due diligence); Spark Optimus (Commercial due diligence); Arthur J Gallagher (Insurance due diligence); White Hart Associates (Regulatory due diligence).
Vendor - Rothschild (M&A); Travers Smith (Legal); PwC (Financial due diligence); OC&C (Commercial due diligence).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Exits
  • UK / Ireland
  • Consumer
  • Secondary buyout
  • Equistone Partners Europe
  • 3i

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013